Top

BMC Infectious Diseases

Published in:

01-12-2021 | Septicemia | Research article

Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: a meta-analysis

Authors: Shan Cong, Tiangang Ma, Xin Di, Chang Tian, Min Zhao, Ke Wang

Published in: BMC Infectious Diseases | Issue 1/2021

Abstract

Background

The aim of the study was to conduct a meta-analysis to evaluate the accuracy of neutrophil CD64, procalcitonin (PCT), and interleukin-6 (IL-6) as markers for the diagnosis of sepsis in adult patients.

Methods

Various databases were searched to collect published studies on the diagnosis of sepsis in adult patients using neutrophil CD64, PCT, and IL-6 levels. Utilizing the Stata SE 15.0 software, forest plots and the area under the summary receiver operating characteristic curves were drawn. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve (AUC) were calculated.

Results

Fifty-four articles were included in the study. The pooled sensitivity, specificity, and AUC of neutrophil CD64 for the diagnosis of sepsis were 0.88 (95% confidence interval [CI], 0.81–0.92), 0.88 (95% CI, 0.83–0.91), and 0.94 (95% CI, 0.91–0.96), respectively. The pooled sensitivity, specificity, and AUC of PCT for the diagnosis of sepsis were 0.82 (95% CI, 0.78–0.85), 0.78 (95% CI, 0.74–0.82), and 0.87 (95% CI, 0.83–0.89), respectively. Subgroup analysis showed that the AUC for PCT diagnosis of intensive care unit (ICU) sepsis was 0.86 (95% CI, 0.83–0.89) and the AUC for PCT diagnosis of non-ICU sepsis was 0.82 (95% CI, 0.78–0.85). The pooled sensitivity, specificity, and AUC of IL-6 for the diagnosis of sepsis were 0.72 (95% CI, 0.65–0.78), 0.70 (95% CI, 0.62–0.76), and 0.77 (95% CI, 0.73–0.80), respectively.

Conclusions

Of the three biomarkers studied, neutrophil CD64 showed the highest diagnostic value for sepsis, followed by PCT, and IL-6. On the other hand, PCT showed a better diagnostic potential for the diagnosis of sepsis in patients with severe conditions compared with that in patients with non-severe conditions.

Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–11. https://doi.org/10.1016/S0140-6736(19)32989-7.CrossRefPubMedPubMedCentral

Verdonk F, Blet A, Mebazaa A. The new sepsis definition: limitations and contribution to research and diagnosis of sepsis. Curr Opin Anaesthesiol. 2017;30(2):200–4. https://doi.org/10.1097/aco.0000000000000446.CrossRefPubMed

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international Sepsis definitions conference. Crit Care Med. 2003;31(4):1250–6. https://doi.org/10.1097/01.Ccm.0000050454.01978.3b.CrossRefPubMed

Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017;9(4):943–5. https://doi.org/10.21037/jtd.2017.03.125.CrossRefPubMedPubMedCentral

Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AFT, Lipman J. Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction insights from a prospective database of ed patients with infection. Chest. 2017;151(3):586–96. https://doi.org/10.1016/j.chest.2016.10.057.CrossRefPubMed

Cheng MP, Stenstrom R, Paquette K, Stabler SN, Akhter M, Davidson AC, et al. Blood culture results before and after antimicrobial administration in patients with severe manifestations of sepsis: a diagnostic study. Ann Intern Med. 2019;171(8):547. https://doi.org/10.7326/m19-1696.CrossRefPubMed

Gguolong C, Jing Y, Haibo Q. Guidelines for the treatment of severe sepsis/septic shock in China (2014):norms and practices. Chin J Internal Med. 2015;54(6):484–5 (In Chinese).

Wagner C, Deppisch R, Denefleh B, Hug F, Andrassy K, Hänsch GM. Expression patterns of the lipopolysaccharide receptor CD14, and the FCgamma receptors CD16 and CD64 on polymorphonuclear neutrophils: data from patients with severe bacterial infections and lipopolysaccharide-exposed cells. Shock. 2003;19(1):5–12. https://doi.org/10.1097/00024382-200301000-00002.CrossRefPubMed

Hoffmann JJML. Neutrophil CD64 as a sepsis biomarker. Biochem Med. 2011;21(3):282–90.CrossRef

10.

Davies J. Procalcitonin. J Clin Pathol. 2015;68(9):675–9. https://doi.org/10.1136/jclinpath-2014-202807.CrossRefPubMed

11.

Matwiyoff GN, Prahl JD, Miller RJ, Carmichael JJ, Amundson DE, Seda G, et al. Immune regulation of procalcitonin: a biomarker and mediator of infection. Inflamm Res. 2012;61(5):401–9. https://doi.org/10.1007/s00011-012-0439-5.CrossRefPubMed

12.

Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R, Manoj G. Procalcitonin:a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017;5(1):51. https://doi.org/10.1186/s40560-017-0246-8.CrossRefPubMedPubMedCentral

13.

Yuzbasioglu Y, Duymaz H, Tanrikulu CS, Halhalli HC, Koc MO, Tandoğan M, et al. Role of Procalcitonin in evaluation of the severity of acute Cholecystitis. Eur J Med. 2016;48(3):162–6. https://doi.org/10.5152/eurasianmedj.2016.0052.CrossRef

14.

Iwase S, Nakada T, Hattori N, Takahashi W, Takahashi N, Aizimu T, et al. Interleukin-6 as a diagnostic marker for infection in critically ill patients: a systematic review and meta-analysis. Am J Emerg Med. 2019;37(2):260–5. https://doi.org/10.1016/j.ajem.2018.05.040.CrossRefPubMed

15.

Wakabayashi A, Sawada K, Nakayama M, Toda A, Kimoto A, Mabuchi S, et al. Targeting interleukin-6 receptor inhibits preterm delivery induced by inflammation. Mol Hum Reprod. 2013;19(11):718–26. https://doi.org/10.1093/molehr/gat057.CrossRefPubMed

16.

Ivancević N, Radenković D, Bumbasirević V, Karamarković A, Jeremić V, Kalezić N, et al. Procalcitonin in preoperative diagnosis of abdominal sepsis. Langenbecks Arch Surg. 2008;393(3):397–403. https://doi.org/10.1007/s00423-007-0239-5.CrossRefPubMed

17.

Muzlovic I, Ihan A, Stubljar D. CD64 index on neutrophils can diagnose sepsis and predict 30-day survival in subjects after ventilator-associated pneumonia. J Infect Dev Ctries. 2016;10(3):260–8. https://doi.org/10.3855/jidc.6532.CrossRefPubMed

18.

Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth. 2005;94(6):767–73. https://doi.org/10.1093/bja/aei143.CrossRefPubMed

19.

Lu H, Zhou J, Wang YL, Chen X. Early diagnosis value of CD64 index levels in peripheral blood on postoperative traumatic sepsis. J Region Anatomy Operative Surg. 2016;25(05):339–42 (In Chinese).

20.

Talebi-Taher M, Babazadeh S, Barati M, Latifnia M. Serum inflammatory markers in the elderly: are they useful in differentiating sepsis from SIRS? Acta Med Iran. 2014;52(6):438–42.PubMed

21.

Zhang HM, Wang XT, Zhang Q, Xia Y, Liu DW. Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatr. 2017;17(1):173. https://doi.org/10.1186/s12877-017-0566-5.CrossRefPubMedPubMedCentral

22.

Shokouhi B, Bookani KR, Ghasemi H, Khalouei M, Rezaei NJ, Samani SM. Diagnostic and prognostic performances of serum procalcitonin in patients with blood stream infections: a parallel, case-control study comprising adults and elderly. Rev Assoc Med Bras. 2017;63(6):521–6. https://doi.org/10.1590/1806-9282.63.06.521.CrossRefPubMed

23.

Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N, et al. Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome:a prospective, observational, cohort study. J Crit Care. 2015;30(1):218.e7. https://doi.org/10.1016/j.jcrc.2014.08.017.CrossRef

24.

Gupta S, Jaswani P, Sharma RK, Agrawal S, Prasad N, Sahu C, et al. Procalcitonin as a diagnostic biomarker of sepsis: a tertiary care Centre experience. J Infect Public Health. 2019;12(3):323–9. https://doi.org/10.1016/j.jiph.2018.11.004.CrossRefPubMed

25.

Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006;34(1):102–7. https://doi.org/10.1097/01.Ccm.0000195012.54682.F3.CrossRefPubMed

26.

Bauer PR, Kashyap R, League SC, Park JG, Block DR, Baumann NA, et al. Diagnostic accuracy and clinical relevance of an inflammatory biomarker panel for sepsis in adult critically ill patients. Diagn Microbiol Infect Dis. 2016;84(2):175–80. https://doi.org/10.1016/j.diagmicrobio.2015.10.003.CrossRefPubMed

27.

Cardelli P, Ferraironi M, Amodeo R, Tabacco F, De Blasi RA, Nicoletti M, et al. Evaluation of neutrophil CD64 expression and procalcitonin as useful markers in early diagnosis of sepsis. Int J Immunopathol Pharmacol. 2008;21(1):43–9. https://doi.org/10.1177/039463200802100106.CrossRefPubMed

28.

Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004;8(4):R234–42. https://doi.org/10.1186/cc2877.CrossRefPubMedPubMedCentral

29.

Cheval C, Timsit JF, Garrouste-Orgeas M, Assicot M, De Jonghe B, Misset B, et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patient. Intensive Care Med. 2000;26(Suppl 2):S153–8. https://doi.org/10.1007/bf02900729.CrossRefPubMed

30.

Davis BH, Olsen SH, Ahmad E, Bigelow NC. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med. 2006;130(5):654–61. https://doi.org/10.5858/2006-130-654-NCIAII.CrossRefPubMed

31.

Dimoula A, Pradier O, Kassengera Z, Dalcomune D, Turkan H, Vincent JL. Serial determinations of neutrophil CD64 expression for the diagnosis and monitoring of sepsis in critically ill patients. Clin Infect Dis. 2004;58(6):820–9. https://doi.org/10.1093/cid/cit936.CrossRef

32.

Du B, Pan JQ, Chen DC, Li Y. Serum procalcition and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious orgin. Chin Med J. 2003;116(4):538–42.PubMed

33.

Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical significance of soluble hemoglobin scavenger receptor CD163 (sCD163) in sepsis, a prospective study. PLoS One. 2012;7(7):e38400. https://doi.org/10.1371/journal.pone.0038400.CrossRefPubMedPubMedCentral

34.

Gaïni S, Koldkjaer OG, Moller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care. 2007;11(4):R76. https://doi.org/10.1186/cc5967.CrossRefPubMedPubMedCentral

35.

Gámez-Díaz LY, Enriquez LE, Matute JD, Velásquez S, Gómez ID, Toro F, et al. Diagnostic accuracy ofHMGB-1,sTREM-1, and CD64 as markers of sepsis in patients recently admitted to the emergency department. Acad Emerg Med. 2011;18(8):807–15. https://doi.org/10.1111/j.1553-2712.2011.01113.x.CrossRefPubMed

36.

Gerrits JH, McLaughlin PMJ, Nienhuis BN, Smit JW, Loef B. Polymorphic mononuclear neutrophils CD64 index for diagnosis of sepsis in postoperative surgical patients and critically ill patients. Clin Chem Lab Med. 2013;51(4):897–905. https://doi.org/10.1515/cclm-2012-0279.CrossRefPubMed

37.

Gibot S, Béné MC, Noel R, Massin F, Guy J, Cravoisy A, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med. 2012;186(1):65–71. https://doi.org/10.1164/rccm.201201-0037OC.CrossRefPubMed

38.

Gros A, Roussel M, Sauvadet E, Gacouin A, Marqué S, Chimot L, et al. The sensitivity of neutrophil CD64 expression as a biomarker of bacterial infection is low in critically ill patients. Intensive Care Med. 2012;38(3):445–52. https://doi.org/10.1007/s00134-012-2483-6.CrossRefPubMed

39.

Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402. https://doi.org/10.1164/ajrccm.164.3.2009052.CrossRefPubMed

40.

Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. 2002;34(7):895–901. https://doi.org/10.1086/339198.CrossRefPubMed

41.

Hsu KH, Chan MC, Wang JM, Lin LY, Wu CL. Comparison of fc gamma receptor expression on neutrophils with procalcitonin for the diagnosis of sepsis in critically ill patients. Respirology. 2011;16(1):152–60. https://doi.org/10.1111/j.1440-1843.2010.01876.x.CrossRefPubMed

42.

Jämsä J, Huotari V, Savolainen ER, Syrjälä H, Ala-Kokko T. Kinetics of leukocyte CD11b and CD64 expression in severe sepsis and non-infectious critical care patients. Acta Anaesthesiol Scand. 2015;59(7):881–91. https://doi.org/10.1111/aas.12515.CrossRefPubMed

43.

Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis. 2013;75(4):342–7. https://doi.org/10.1016/j.diagmicrobio.2012.12.011.CrossRefPubMed

44.

Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein,procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38. https://doi.org/10.1186/cc5723.CrossRefPubMedPubMedCentral

45.

Latour-Pérez J, Alcalá-López A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Med Int. 2010;43(9):720–4. https://doi.org/10.1016/j.clinbiochem.2010.03.001.CrossRef

46.

Lewis SM, Treacher DF, Edgeworth J, Mahalingam G, Brown CS, Mare TA, et al. Expression of CD11c and EMR2 on neutrophils:potential diagnostic biomarkers for sepsis and systemic inflammation. Clin Exp Immunol. 2015;182(2):184–94. https://doi.org/10.1111/cei.12679.CrossRefPubMedPubMedCentral

47.

Mat-Nor MB, Ralib AMD, Abdulah NZ, Pickering JW. The diagnostic ability of procalcitonin and interleukin-6 to differentiate infectious from noninfectious systemic inflammatory response syndrome and to predict mortality. J Crit Care. 2016;33:245–51. https://doi.org/10.1016/j.jcrc.2016.01.002.CrossRefPubMed

48.

Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, IL-6, or LBP. Crit Care Res Pract. 2011;2011:594645–6. https://doi.org/10.1155/2011/594645.CrossRefPubMedPubMedCentral

49.

Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28(4):977–83. https://doi.org/10.1097/00003246-200004000-00011.CrossRefPubMed

50.

Papadimitriou-Olivgeris M, Lekka K, Zisimopoulos K, Spiliopoulou I, Logothetis D, Theodorou G, et al. Role of CD64 expression on neutrophils in the diagnosis of sepsis and the prediction of mortality in adult critically ill patients. Diagn Microbiol Infect Dis. 2015;82(3):234–9. https://doi.org/10.1016/j.diagmicrobio.2015.03.022.CrossRefPubMed

51.

Righi S, Santambrogio L, Monsagrati A, Saliu M, Locati L, Radrizzani D. Clinical evaluation of neutrophil CD64 as a diagnostic marker of infection in a poly valent intensive care unit. Infect Dis Clin Pract. 2014;22(1):32–7. https://doi.org/10.1097/IPC.0b013e31828f4b6a.CrossRef

52.

Ruokonen E, Ilkka L, Niskanen M, Takala J. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand. 2002;46(4):398–404. https://doi.org/10.1034/j.1399-6576.2002.460412.x.CrossRefPubMed

53.

Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Köhl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med. 2000;28(4):2793–8. https://doi.org/10.1097/00003246-200008000-00019.CrossRefPubMed

54.

Spoto S, Cella E, de Cesaris M, Locorriere L, Mazzaroppi S, Nobile E, et al. Procalcitonin and mr-proadrenomedullin combination with SOFA and qSOFA scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock. 2018;50(1):44–52. https://doi.org/10.1097/shk.0000000000001023.CrossRefPubMed

55.

Suprin E, Camus C, Gacouin A, Le Tulzo Y, Lavoue S, Feuillu A, et al. Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med. 2000;26(9):1232–8. https://doi.org/10.1007/s001340000580.CrossRefPubMed

56.

Tan TL, Ahmad NS, Nasuruddin DN, Ithnin A, Arifin K, Zaini IZ, et al. CD64 and group II secretory phospholipase A2(sPLA2-IIA) as biomarkers for distinguishing adult sepsis and bacterial infections in the emergency department. PLoS One. 2016;11(3):e0152065. https://doi.org/10.1371/journal.pone.0152065.CrossRefPubMedPubMedCentral

57.

Tromp M, Lansdorp B, Bleeker-Rovers CP, Gunnewiek JMK, Kullberg BJ, Pickkers P. Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. J Inf Secur. 2012;65(4):292–301. https://doi.org/10.1016/j.jinf.2012.06.004.CrossRef

58.

Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2012;43(1):97–106. https://doi.org/10.1016/j.jemermed.2011.05.072.CrossRefPubMed

59.

Wang H, Yin F, Shen DX, Zhang YJ, Luo YP, Liu CJ, et al. Predictive value of procalcitonin for excluding bloodstream infection:results of a retrospective study and utility of a rapid, quantitative test for procalcitonin. J Int Med Res. 2013;41(5):1671–81. https://doi.org/10.1177/0300060513497558.CrossRefPubMed

60.

Huang WP, Jiang WQ, Hu B, Ye H, Zeng HK. Significance of serum procalcitonin levels in the evaluation of severity and prognosis of patients with systemic inflammatory response syndrome. Chin Crit Care Med. 2012;05(24):294–7 (In Chinese).

61.

Shao JS, Zhou LX, Li YN, Chen S, Yu TO. Diagnostic application of neutrophil CD64 expression in sepsis. Chin J Crit Care Med. 2014;34(7):1–4 (In Chinese).

62.

Tang YM, Cai QW, Ye YS, Lei ZH. Three indicators combined detection of the application of ICU in early diagnosis of sepsis patients. Int J Lab Med. 2017;38(01):61–2 (In Chinese).

63.

Wang B, Wang H. Clinical value of C-reactive protein, procalcitonin, neutrophil surface CD35 and CD64 in the diagnosis of sepsis. J Clin Exp Med. 2017;16(08):752–5 (In Chinese).

64.

Xing YB, Dai LM, Zhao ZH, Li ZW, Li C. Diagnostic and prognostic value of procalcitonin and common inflammatory markers combining SOFA score in patients with sepsis in early stage. Chin Crit Care Med. 2008;20(01):23–8 (In Chinese).

65.

Xu JY, Chen JH, Ou YJ, Gu Q, Liu Y, Wang Y. Early diagnosis value of neutrophil CD64 in adult sepsis. Chin J Hosp Infect Dis. 2009;19(05):596–8 (In Chinese).

66.

Zhang H, Yi SH, Zhang XW, Jin FL. The value of sTREM-1 and neutrophil surface CD64 expression in early diagnosis of sepsis. J Int Lab Med. 2012;33(13):1590–2 (In Chinese).

67.

Zhao R, Dong SM. Clinical value of serum endocan and procalcitonin in early diagnosis and prognosis of sepsis. Chin Crit Care Med. 2017;29(4):321–6. (In Chinese). https://doi.org/10.3760/cma.j.issn.2095-4352.2017.04.007.CrossRef

68.

Zhao RY, Bao YM, Yang YQ. Clinical study of serum PCT, IL-6, NT-proBNP, CTnI and DD levels in early diagnosis of emergency sepsis patients. Label Immun Clin Med. 2016;23(6):613–6 (In Chinese).

69.

Zhao YZ, Li CS. Diagnostic value of biomarker combination in patients with emergency sepsis and severe sepsis. Chin Crit Care Med. 2014;26(3):153–8. (In Chinese). https://doi.org/10.3760/cma.j.issn.2095-4352.2014.03.006.CrossRef

70.

Wang X, Li ZY, Zeng L, Zhang AQ, Pan W, Gu W, et al. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Crit Care. 2016;20(1):172. https://doi.org/10.1186/s13054-015-0972-z.CrossRefPubMedPubMedCentral

71.

Li S, Huang XM, Chen ZP, Zhong HZ, Peng QL, Deng Y, et al. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection: a meta analysis. Int J Infect Dis. 2013;17(1):e12–23. https://doi.org/10.1016/j.ijid.2012.07.017.CrossRefPubMed

72.

Ricarte-Bratti JP, Brizuela NY, Jaime-Albarran N, Montrull HL. IL-6, MMP 3 and prognosis in previously healthy sepsis patients. Rev Fac Cien Med Univ Nac Cordoba. 2017;74(2):99–106. https://doi.org/10.31053/1853.0605.v74.n2.14608.CrossRefPubMed

73.

Gür A, Oguzturk H, Köse A, Turtay MG, Ersan V, Bayindir Y, et al. Prognostic value of procalcitonin, CRP, serum amyloid A, lactate and IL-6 markers in liver transplant patients admitted to ED with suspected infection. In Vivo. 2017;31(6):1179–85. https://doi.org/10.21873/invivo.11187.CrossRefPubMedPubMedCentral

74.

Guan JJ, Wang ZY, Liu XY, Jiang YJ, Gao QQ, Wu Q, et al. IL-6 and IL-10 closely correlate with bacterial bloodstream infection. Iran J Immunol. 2020;17(3):185–203. https://doi.org/10.22034/iji.2020.87266.1793.CrossRefPubMed

75.

Zhao YZ, Li CS. Diagnostic value of a combination of biomarkers in patients with sepsis and severe sepsis in emergency department. Chin Crit Care Med. 2014;26(03):153–8 (In Chinese).

76.

Yunus I, Fasih A, Wang YZ. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLoS One. 2018;13(11):e0206527. https://doi.org/10.1371/journal.pone.0206527.CrossRefPubMedPubMedCentral

Title: Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: a meta-analysis
Authors: Shan Cong
Tiangang Ma
Xin Di
Chang Tian
Min Zhao
Ke Wang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Septicemia
Septicemia
Published in: BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-021-06064-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

A 10-year cross-sectional retrospective study on Kawasaki disease in Iranian children: incidence, clinical manifestations, complications, and treatment patterns

Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial

Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

Intestinal protozoa in hospitalized under-five children with diarrhoea in Nampula – a cross-sectional analysis in a low-income setting in northern Mozambique

Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients

Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage